Edition:
United Kingdom

Neogenomics Inc (NEO.OQ)

NEO.OQ on NASDAQ Stock Exchange Capital Market

9.19USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$9.19
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
109,399
52-wk High
$11.55
52-wk Low
$7.14

Latest Key Developments (Source: Significant Developments)

NeoGenomics reports Q3 adj earnings per share of $0.01
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Neogenomics Inc :NeoGenomics reports revenue of $63.1 million on 17 percent volume growth and 11 percent reduction in average cost per test in the third quarter of 2017.Q3 adjusted earnings per share $0.01.Q3 revenue $63.1 million versus I/B/E/S view $63.5 million.Q3 earnings per share view $0.02 -- Thomson Reuters I/B/E/S.Sees Q4 loss per share $0.03 to $0.04.Sees Q4 revenue $65 million to $67 million.Q3 GAAP loss per share $0.10.Q4 earnings per share view $0.04, revenue view $66.8 million -- Thomson Reuters I/B/E/S.NeoGenomics Inc - expects ‍Q4 adjusted diluted EPS to be $0.04 - $0.05 per share​.  Full Article

NeoGenomics sees Q3 revenue of about $63.1 mln
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - NeoGenomics Inc :NeoGenomics announces preliminary quarter 3 results, financial impacts of hurricanes and summary quarter 4 guidance.NeoGenomics Inc - ‍it expects to report quarter 3 revenue of approximately $63.1 million and adjusted EBITDA of approximately $6.0 million​.NeoGenomics Inc - ‍NeoGenomics estimates that hurricanes Harvey and Irma depressed revenue by approximately $1.0 million in quarter 3​.NeoGenomics inc - ‍in addition, as a result of divestiture of pathlogic, Q3 revenue will be approximately $1.3 million less than in quarter 2​.NeoGenomics Inc - ‍expects consolidated revenue of $65 million - $67 million and adjusted EBITDA of $9 million -10 million in Q4​.NeoGenomics-For Q3,expects to record $1.3 million revenue adjustment to reflect change in process for estimating revenue for unbilled tests at quarter-end​.Q3 revenue view $65.9 million -- Thomson Reuters I/B/E/S.Q4 revenue view $69.1 million -- Thomson Reuters I/B/E/S.  Full Article

NeoGenomics Q2 adjusted earnings per share $0.04
Tuesday, 26 Jul 2016 

Neogenomics Inc : Neogenomics reports 159% revenue growth to $63.1 million and strong gains in profitability in the second quarter of 2016 . Q2 adjusted earnings per share $0.04 . Q2 loss per share $0.07 . Q2 revenue $63.1 million versus i/b/e/s view $61.1 million . Q2 earnings per share view $0.03 -- Thomson Reuters I/B/E/S .Neogenomics inc says reiterated guidance for fiscal year 2016.  Full Article

Neogenomics files for stock shelf of up to $200 mln
Friday, 17 Jun 2016 

Neogenomics Inc :Files for stock shelf of up to $200 million - SEC filing.  Full Article

Neogenomics Inc gives FY 2016 guidance
Tuesday, 1 Mar 2016 

Neogenomics Inc:Expects FY 2016 revenue to be in the range of $240 - $250 million.Expects FY 2016 adjusted EBITDA to be in the range of $33 - $38 million.Expects FY 2016 adjusted net income to be in the range of $7 - $12 million, and adjusted diluted EPS to be in the range of $0.07 - $0.12 per share.  Full Article

NeoGenomics Inc completes acquisition of Clarient Inc
Wednesday, 30 Dec 2015 

NeoGenomics Inc:Announced that it has completed the acquisition of Clarient, Inc. and its wholly-owned subsidiary Clarient Diagnostic Services, Inc.  Full Article

BRIEF-Neogenomics Inc files for non-timely 10-Q - SEC filing ‍​

* Neogenomics Inc files for non-timely 10-Q - SEC filing ‍​ Source text: (http://bit.ly/2AozWFk) Further company coverage: